Developer docs
API playgroundTry for free, no card

Search company profiles

Treatment Action Group

Full company profile

uuid000c8ko

Namestring
Treatment Action Group
Legal namestring
Treatment Action Group
Company typeenum
Private
Founded yearint
1992
Descriptiontext

Treatment Action Group (TAG) is an independent, activist, community-based research and policy think tank founded in January 1992 by members of ACT UP. Based in New York City with a remote team of approximately 20 staff, TAG is dedicated to accelerating the fight against HIV, tuberculosis (TB), and hepatitis C virus (HCV) through policy advocacy, scientific research, and community organizing. It serves researchers, clinicians, policymakers, donors, and affected communities in the U.S. and globally.

TAG's core deliverables include the Pipeline Report — an authoritative assessment of HIV, TB, and HCV research and development — the TAGline newsletter, annual TB Research Funding Trends analyses, and clinical trials databases that function as information infrastructure for the field. The organization earns revenue through a nonprofit funding mix: foundation grants (historically including a $4.7M Bill & Melinda Gates Foundation grant in 2007 and ongoing Unitaid support), corporate sponsorships, individual donations, and limited-edition art fundraising. It maintains public accountability through a Platinum Seal of Transparency and a 4-star Charity Navigator rating.

Operationally, TAG functions as a coalition partner within a broader advocacy ecosystem, working alongside Black AIDS Institute, Southern AIDS Coalition, KNCV, Stop TB Partnership, AfroCAB, and NIAID clinical trial networks. Its 2026 communications director hire, the Wakefield Award, and the Southern AIDS Coalition partnership mark its current strategic emphasis on geographic expansion (U.S. South), communications capacity, and coalition-driven policy influence.

Short descriptiontext

Treatment Action Group (TAG) is an independent, activist research and policy think tank founded in 1992 that fights HIV, tuberculosis, and hepatitis C through scientific research, policy advocacy, and community organizing, serving researchers, clinicians, donors, and affected communities globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
HIV/AIDS advocacy, tuberculosis research, hepatitis C policy, public health advocacy, treatment access
Industry1 code
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)
NAICS code3 codes
  • Other Social Advocacy Organizations813319
  • Social Advocacy Organizations8133
  • Voluntary Health Organizations813212
SIC code2 codes
  • Services-Social Services8300
  • Services-Health Services8000
Product category
Public Health Advocacy and Policy Research
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Individual Donations
TypeGrants Donations
Description

TAG receives donations from individual supporters through direct contributions, monthly giving programs, stock gifts, and planned giving/bequests.

treatmentactiongroup.org
2Foundation Grants
TypeGrants Donations
Description

TAG receives grants from foundations including Bill & Melinda Gates Foundation ($4.7 million grant in 2007 for TB/HIV research) and Unitaid for various projects including ASCENT DR-TB and LONGEVITY projects.

treatmentactiongroup.org
3Corporate Sponsorship
TypeGrants Donations
Description

TAG receives corporate sponsorships for its annual Research in Action Awards (RIAA) event, including sponsors at various levels ($25,000, $10,000, $8,000, $2,500, $1,000).

treatmentactiongroup.org
4Limited Art Editions
TypeGrants Donations
Description

TAG sells limited edition artworks donated by visual artists at its annual RIAA event as a fundraising mechanism.

treatmentactiongroup.org
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Others
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Treatment Action Group is an independent, activist, community-based research and policy think tank that produces research publications, policy reports, and advocacy resources to accelerate treatment research and maximize equitable access to prevention, diagnosis, and treatment for HIV, tuberculosis, and hepatitis C. Its primary deliverables include the annual HIV/HCV/TB Pipeline Report, TAGline newsletter, TB Research Funding Trends reports, and the Research Toward a Cure clinical trials database. TAG mobilizes affected communities, scientists, and policymakers through open collective action.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Treatment Action Group (TAG) is an independent activist research and policy organization focused on ending HIV, tuberculosis (TB), and hepatitis C (HCV) pandemics. Rather than a technology product company, TAG offers a portfolio of research publications and advocacy resources including the annual Pipeline Report covering HIV/HCV/TB diagnostics and treatments, TAGline newsletter, TB Research Funding Trends reports, HIV cure-related clinical trials database, HIV & Aging resources, Cure-Related Research Resources, and the Long-Acting Technologies Resource Compendium. These publications and databases serve as the primary tools for community advocates, researchers, and policymakers working in global health.

Product and service5 records
1Pipeline Report
CategoryResearch Publication
Description

Annual comprehensive review providing an overview of research and development innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). Includes detailed updates on antiretroviral therapy, HIV vaccines, PrEP, cure research, TB diagnostics, and TB treatment. Widely cited by researchers as an authoritative reference.

2TAGline
CategoryNewsletter Publication
Description

Regular publication providing news on the fight to end HIV/AIDS, hepatitis C, and tuberculosis. Documents advocacy efforts, policy positions, and organizational activities for community advocates, researchers, and policymakers.

3TB Research Funding Trends Report
CategoryResearch Publication
Description

Annual report tracking public, private, philanthropic, and multilateral institution spending on TB research and development across six areas: basic science, diagnostics, drugs, vaccines, operational research, and infrastructure. Published since 2006 as the leading reference document on TB R&D investments.

4Research Toward a Cure Trials Database
CategoryClinical Trials Resource
Description

Monthly-updated listing of clinical trials and observational studies related to HIV cure research, derived from clinicaltrials.gov. Includes information on trial design, enrollment criteria, principal investigators, locations, and published results. Used by advocates, researchers, and communities to track progress toward an HIV cure.

5Long-Acting Technologies Resource Compendium
CategoryResearch Resource Compendium
Description

Non-exhaustive list of materials covering long-acting technologies for hepatitis C, latent tuberculosis infection, and malaria under the LONGEVITY Project. Includes trials tracker and illustrated glossary, advancing research and uptake of long-acting technologies for communities most in need.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG partners with Black AIDS Institute to facilitate robust community engagement in domestic HIV research. Together they developed the We The People Research Cohort, addressing lack of minority representation within research protocol development and participation.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG partners with Southern AIDS Coalition on community engagement efforts, particularly in the Southern U.S. where HIV impact is disproportionately high. Together they support HIV advocacy training centered on Black and Brown community needs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

TAG's partnership with Black AIDS Institute and Southern AIDS Coalition has support from Fred Hutch (Fred Hutchinson Cancer Research Center).

Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG partners with KNCV Tuberculosis Foundation on the ASCENT DR-TB project, funded by Unitaid, aiming to improve access to shorter, safer, and more effective treatment regimens for drug-resistant TB and comprehensive person-centered quality care.

5Stop TB Partnership
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG has partnered with Stop TB Partnership since 2008 for international advocacy on TB/HIV research and treatment, including holding satellite meetings at Union World Conferences.

treatmentactiongroup.org
6Long-Acting Technologies Community Advisory Board (LAT CAB)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG and AfroCAB formed the Long-Acting Technologies Community Advisory Board (LAT CAB) to implement meaningful, equitable solutions and research to serve communities that need them most. LAT CAB advances LAT research and uptake under the Unitaid-funded LONGEVITY project.

treatmentactiongroup.org
7African Community Advisory Board (AfroCAB)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

TAG co-founded LAT CAB with AfroCAB to advance research and uptake of long-acting technologies for communities most in need, particularly under the Unitaid-funded LONGEVITY project.

treatmentactiongroup.org
8AIDS Research Advisory Council (ARAC)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

TAG provides recommendations to ARAC on NIAID's support of HIV clinical trial networks including ACTG, IMPAACT, HPTN, and HVTN.

treatmentactiongroup.org
9Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ACTG is one of the four Division of AIDS-sponsored HIV clinical research networks that TAG advocates for continued NIAID funding and support.

treatmentactiongroup.org
10International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

IMPAACT is one of the four HIV clinical research networks that TAG supports through advocacy to ensure continued funding and comprehensive research portfolios.

treatmentactiongroup.org
11HIV Prevention Trials Network (HPTN)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HPTN is one of the four major HIV clinical research networks that TAG advocates for, focusing on prevention trials.

treatmentactiongroup.org
Strategic tierCoreTypeStrategic or Co-development Partner
Description

HVTN is the largest publicly funded collaboration facilitating HIV/AIDS vaccine evaluations. TAG works to ensure continued support and funding for the network.

13COVID-19 Prevention Network (CoVPN)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

TAG developed fact sheets in partnership with CoVPN and Black AIDS Institute to foster community understanding of COVID-19 vaccine research.

treatmentactiongroup.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Larger global health nonprofit delivering healthcare and fighting disease including HIV and TB in resource-poor settings. Broader incumbent operating in the same disease areas as TAG but with a service-delivery rather than research/policy focus.

TypeDirect peer
Description

Global nonprofit product development partnership working to develop and deliver faster, better tuberculosis treatments. Direct peer in the TB advocacy/R&D space, with overlap on the ASCENT DR-TB project KNCV partnership ecosystem and shared Unitaid funding streams.

TypeDirect peer
Description

U.S.-based national organization that advocates for people living with and affected by HIV. Direct peer in domestic HIV policy advocacy, with overlapping focus on Southern U.S. jurisdictions, Black and Brown communities, and Ending the Epidemic initiatives.

TypeBroad incumbent
Description

Global health organization working to save lives by improving access to quality healthcare for HIV/AIDS, TB, and other diseases. Comparable on treatment access advocacy and partnerships with ministries of health, with significantly larger scale and operational footprint.

TypeDirect peer
Description

Activist organization fighting for equitable global access to HIV treatment and medicines. Direct peer sharing TAG's policy/advocacy focus and ACT UP lineage, with comparable size and mission around treatment access and drug pricing activism.

TypeDirect peer
Description

One of the world's leading HIV/AIDS research and advocacy nonprofits. Directly comparable to TAG as a disease-focused advocacy and research funder, though amfAR is significantly larger and emphasizes direct research funding while TAG focuses on policy and access advocacy.

TypeBroad incumbent
Description

Massive international medical humanitarian organization that combines direct service delivery with high-profile advocacy on access to medicines. Comparable on the advocacy and policy side, particularly on TB drug pricing and access issues that intersect with TAG's mission.

TypeDirect peer
Description

Global coalition of people living with HIV and community activists focused on access to optimal HIV treatment. Direct peer in treatment-access advocacy with similar lean operating model and community-led approach, especially in middle-income countries.

TypeDirect peer
Description

International not-for-profit R&D organization developing treatments for neglected diseases including HCV and TB. Comparable model of advocating for and accelerating R&D for diseases disproportionately affecting low-income populations, with overlapping funder relationships.

TypeDirect peer
Description

Global HIV prevention research advocacy organization focused on accelerating the development and delivery of HIV prevention tools (vaccines, PrEP). Direct peer with overlapping HIV cure/vaccine research advocacy and similar publication-driven model (think tank/research outputs).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Treatment Action Group

Public Health Advocacy and Policy Researchtreatmentactiongroup.org

Treatment Action Group (TAG) is an independent, activist research and policy think tank founded in 1992 that fights HIV, tuberculosis, and hepatitis C through scientific research, policy advocacy, and community organizing, serving researchers, clinicians, donors, and affected communities globally.

What Treatment Action Group does

Treatment Action Group (TAG) is an independent, activist, community-based research and policy think tank founded in January 1992 by members of ACT UP. Based in New York City with a remote team of approximately 20 staff, TAG is dedicated to accelerating the fight against HIV, tuberculosis (TB), and hepatitis C virus (HCV) through policy advocacy, scientific research, and community organizing. It serves researchers, clinicians, policymakers, donors, and affected communities in the U.S. and globally.

TAG's core deliverables include the Pipeline Report — an authoritative assessment of HIV, TB, and HCV research and development — the TAGline newsletter, annual TB Research Funding Trends analyses, and clinical trials databases that function as information infrastructure for the field. The organization earns revenue through a nonprofit funding mix: foundation grants (historically including a $4.7M Bill & Melinda Gates Foundation grant in 2007 and ongoing Unitaid support), corporate sponsorships, individual donations, and limited-edition art fundraising. It maintains public accountability through a Platinum Seal of Transparency and a 4-star Charity Navigator rating.

Operationally, TAG functions as a coalition partner within a broader advocacy ecosystem, working alongside Black AIDS Institute, Southern AIDS Coalition, KNCV, Stop TB Partnership, AfroCAB, and NIAID clinical trial networks. Its 2026 communications director hire, the Wakefield Award, and the Southern AIDS Coalition partnership mark its current strategic emphasis on geographic expansion (U.S. South), communications capacity, and coalition-driven policy influence.

Treatment Action Group firmographics

Firmographics
Name
Treatment Action Group
Legal name
Treatment Action Group
Website
https://treatmentactiongroup.org
Company type
Private
Founded year
1992
Operating status
Operating
Headcount range
11–50 employees
Short description
Treatment Action Group (TAG) is an independent, activist research and policy think tank founded in 1992 that fights HIV, tuberculosis, and hepatitis C through scientific research, policy advocacy, and community organizing, serving researchers, clinicians, donors, and affected communities globally.
Ownership category
akta.pro rank

Treatment Action Group industry classification

Industry
Product category
Public Health Advocacy and Policy Research
NAICS
Other Social Advocacy Organizations (813319), Social Advocacy Organizations (8133), Voluntary Health Organizations (813212)
SIC
Services-Social Services (8300), Services-Health Services (8000)
akta.pro industry
PRIMARYHLAJAKAN
Global Health Research, Evidence & Technical Assistance Organizations
Healthcare & Life Sciences/Public Health, Government & Regulators/Global Health & Development Agencies (NGOs/Multilaterals)

Keywords

  • HIV/AIDS advocacy
  • Tuberculosis research
  • Hepatitis C policy
  • Public health advocacy
  • Treatment access

Where Treatment Action Group is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Treatment Action Group business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

  1. Individual Donations: TAG receives donations from individual supporters through direct contributions, monthly giving programs, stock gifts, and planned giving/bequests.
  2. Foundation Grants: TAG receives grants from foundations including Bill & Melinda Gates Foundation ($4.7 million grant in 2007 for TB/HIV research) and Unitaid for various projects including ASCENT DR-TB and LONGEVITY projects.
  3. Corporate Sponsorship: TAG receives corporate sponsorships for its annual Research in Action Awards (RIAA) event, including sponsors at various levels ($25,000, $10,000, $8,000, $2,500, $1,000).
  4. Limited Art Editions: TAG sells limited edition artworks donated by visual artists at its annual RIAA event as a fundraising mechanism.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Treatment Action Group product offering

Product offering

Core offering

Treatment Action Group is an independent, activist, community-based research and policy think tank that produces research publications, policy reports, and advocacy resources to accelerate treatment research and maximize equitable access to prevention, diagnosis, and treatment for HIV, tuberculosis, and hepatitis C. Its primary deliverables include the annual HIV/HCV/TB Pipeline Report, TAGline newsletter, TB Research Funding Trends reports, and the Research Toward a Cure clinical trials database. TAG mobilizes affected communities, scientists, and policymakers through open collective action.

Product overview

Treatment Action Group (TAG) is an independent activist research and policy organization focused on ending HIV, tuberculosis (TB), and hepatitis C (HCV) pandemics. Rather than a technology product company, TAG offers a portfolio of research publications and advocacy resources including the annual Pipeline Report covering HIV/HCV/TB diagnostics and treatments, TAGline newsletter, TB Research Funding Trends reports, HIV cure-related clinical trials database, HIV & Aging resources, Cure-Related Research Resources, and the Long-Acting Technologies Resource Compendium. These publications and databases serve as the primary tools for community advocates, researchers, and policymakers working in global health.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pipeline Report Annual comprehensive review providing an overview of research and development innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). Includes detailed updates on antiretroviral therapy, HIV vaccines, PrEP, cure research, TB diagnostics, and TB treatment. Widely cited by researchers as an authoritative reference.
  • TAGline Regular publication providing news on the fight to end HIV/AIDS, hepatitis C, and tuberculosis. Documents advocacy efforts, policy positions, and organizational activities for community advocates, researchers, and policymakers.
  • TB Research Funding Trends Report Annual report tracking public, private, philanthropic, and multilateral institution spending on TB research and development across six areas: basic science, diagnostics, drugs, vaccines, operational research, and infrastructure. Published since 2006 as the leading reference document on TB R&D investments.
  • Research Toward a Cure Trials Database Monthly-updated listing of clinical trials and observational studies related to HIV cure research, derived from clinicaltrials.gov. Includes information on trial design, enrollment criteria, principal investigators, locations, and published results. Used by advocates, researchers, and communities to track progress toward an HIV cure.
  • Long-Acting Technologies Resource Compendium Non-exhaustive list of materials covering long-acting technologies for hepatitis C, latent tuberculosis infection, and malaria under the LONGEVITY Project. Includes trials tracker and illustrated glossary, advancing research and uptake of long-acting technologies for communities most in need.

Companies that use Treatment Action Group

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Treatment Action Group technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Treatment Action Group partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered core and minor.

  • Black AIDS Institute (BAI)coreStrategic or Co-development PartnerTAG partners with Black AIDS Institute to facilitate robust community engagement in domestic HIV research. Together they developed the We The People Research Cohort, addressing lack of minority representation within research protocol development and participation.
  • Southern AIDS Coalition (SAC)coreStrategic or Co-development PartnerTAG partners with Southern AIDS Coalition on community engagement efforts, particularly in the Southern U.S. where HIV impact is disproportionately high. Together they support HIV advocacy training centered on Black and Brown community needs.
  • Fred HutchminorStrategic or Co-development PartnerTAG's partnership with Black AIDS Institute and Southern AIDS Coalition has support from Fred Hutch (Fred Hutchinson Cancer Research Center).
  • KNCV Tuberculosis FoundationcoreStrategic or Co-development PartnerTAG partners with KNCV Tuberculosis Foundation on the ASCENT DR-TB project, funded by Unitaid, aiming to improve access to shorter, safer, and more effective treatment regimens for drug-resistant TB and comprehensive person-centered quality care.
  • Stop TB PartnershipcoreStrategic or Co-development PartnerTAG has partnered with Stop TB Partnership since 2008 for international advocacy on TB/HIV research and treatment, including holding satellite meetings at Union World Conferences.
  • Long-Acting Technologies Community Advisory Board (LAT CAB)coreStrategic or Co-development PartnerTAG and AfroCAB formed the Long-Acting Technologies Community Advisory Board (LAT CAB) to implement meaningful, equitable solutions and research to serve communities that need them most. LAT CAB advances LAT research and uptake under the Unitaid-funded LONGEVITY project.
  • African Community Advisory Board (AfroCAB)coreStrategic or Co-development PartnerTAG co-founded LAT CAB with AfroCAB to advance research and uptake of long-acting technologies for communities most in need, particularly under the Unitaid-funded LONGEVITY project.
  • AIDS Research Advisory Council (ARAC)minorStrategic or Co-development PartnerTAG provides recommendations to ARAC on NIAID's support of HIV clinical trial networks including ACTG, IMPAACT, HPTN, and HVTN.
  • Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections (ACTG)coreStrategic or Co-development PartnerACTG is one of the four Division of AIDS-sponsored HIV clinical research networks that TAG advocates for continued NIAID funding and support.
  • International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT)coreStrategic or Co-development PartnerIMPAACT is one of the four HIV clinical research networks that TAG supports through advocacy to ensure continued funding and comprehensive research portfolios.
  • HIV Prevention Trials Network (HPTN)coreStrategic or Co-development PartnerHPTN is one of the four major HIV clinical research networks that TAG advocates for, focusing on prevention trials.
  • HIV Vaccine Trials Network (HVTN)coreStrategic or Co-development PartnerHVTN is the largest publicly funded collaboration facilitating HIV/AIDS vaccine evaluations. TAG works to ensure continued support and funding for the network.
  • COVID-19 Prevention Network (CoVPN)minorStrategic or Co-development PartnerTAG developed fact sheets in partnership with CoVPN and Black AIDS Institute to foster community understanding of COVID-19 vaccine research.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Treatment Action Group competitors and assessment

Company assessment

Broad incumbents

  • Partners in Health: Larger global health nonprofit delivering healthcare and fighting disease including HIV and TB in resource-poor settings. Broader incumbent operating in the same disease areas as TAG but with a service-delivery rather than research/policy focus.
  • Clinton Health Access Initiative (CHAI): Global health organization working to save lives by improving access to quality healthcare for HIV/AIDS, TB, and other diseases. Comparable on treatment access advocacy and partnerships with ministries of health, with significantly larger scale and operational footprint.
  • Médecins Sans Frontières / Doctors Without Borders: Massive international medical humanitarian organization that combines direct service delivery with high-profile advocacy on access to medicines. Comparable on the advocacy and policy side, particularly on TB drug pricing and access issues that intersect with TAG's mission.

Direct peers

  • TB Alliance: Global nonprofit product development partnership working to develop and deliver faster, better tuberculosis treatments. Direct peer in the TB advocacy/R&D space, with overlap on the ASCENT DR-TB project KNCV partnership ecosystem and shared Unitaid funding streams.
  • AIDS United: U.S.-based national organization that advocates for people living with and affected by HIV. Direct peer in domestic HIV policy advocacy, with overlapping focus on Southern U.S. jurisdictions, Black and Brown communities, and Ending the Epidemic initiatives.
  • Health GAP (Global Access Project): Activist organization fighting for equitable global access to HIV treatment and medicines. Direct peer sharing TAG's policy/advocacy focus and ACT UP lineage, with comparable size and mission around treatment access and drug pricing activism.
  • amfAR (Foundation for AIDS Research): One of the world's leading HIV/AIDS research and advocacy nonprofits. Directly comparable to TAG as a disease-focused advocacy and research funder, though amfAR is significantly larger and emphasizes direct research funding while TAG focuses on policy and access advocacy.
  • International Treatment Preparedness Coalition (ITPC): Global coalition of people living with HIV and community activists focused on access to optimal HIV treatment. Direct peer in treatment-access advocacy with similar lean operating model and community-led approach, especially in middle-income countries.
  • DNDi (Drugs for Neglected Diseases initiative): International not-for-profit R&D organization developing treatments for neglected diseases including HCV and TB. Comparable model of advocating for and accelerating R&D for diseases disproportionately affecting low-income populations, with overlapping funder relationships.
  • AVAC (AIDS Vaccine Advocacy Coalition): Global HIV prevention research advocacy organization focused on accelerating the development and delivery of HIV prevention tools (vaccines, PrEP). Direct peer with overlapping HIV cure/vaccine research advocacy and similar publication-driven model (think tank/research outputs).

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Treatment Action Group social profiles

Digital presence

Treatment Action Group financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Treatment Action Group leadership team

Management profile

Number of profiles

Profiles15 records

Treatment Action Group funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Treatment Action Group M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treatment Action Group

What does Treatment Action Group do?

Treatment Action Group is an independent, activist, community-based research and policy think tank that produces research publications, policy reports, and advocacy resources to accelerate treatment research and maximize equitable access to prevention, diagnosis, and treatment for HIV, tuberculosis, and hepatitis C. Its primary deliverables include the annual HIV/HCV/TB Pipeline Report, TAGline newsletter, TB Research Funding Trends reports, and the Research Toward a Cure clinical trials database. TAG mobilizes affected communities, scientists, and policymakers through open collective action.

Is Treatment Action Group a public or private company?

Treatment Action Group is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Treatment Action Group founded?

Treatment Action Group was founded in 1992. It employs 11 to 50 people.

Where is Treatment Action Group based?

Treatment Action Group is headquartered in New York, United States, in the North America region.

How does Treatment Action Group make money?

Four revenue lines are on record. Individual Donations are the primary driver. The others are foundation Grants, corporate Sponsorship and limited Art Editions.

Who are Treatment Action Group's main competitors?

Broad incumbents on record are Partners in Health, Clinton Health Access Initiative (CHAI) and Médecins Sans Frontières / Doctors Without Borders. Direct peers are TB Alliance, AIDS United, Health GAP (Global Access Project), amfAR (Foundation for AIDS Research), International Treatment Preparedness Coalition (ITPC), DNDi (Drugs for Neglected Diseases initiative) and AVAC (AIDS Vaccine Advocacy Coalition).

Does Treatment Action Group have an API?

No public API is recorded for Treatment Action Group.

What industry is Treatment Action Group in?

Treatment Action Group's product category is Public Health Advocacy and Policy Research. Its primary akta.pro industry code is HLAJAKAN, Global Health Research, Evidence & Technical Assistance Organizations. Its NAICS code is 813319 and its SIC code is 8300.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireTreatment Action Group to Honor Gloria Reuben at 2025 Research in Action AwardsTreatment Action Group (TAG) announced that actress, author, and advocate Gloria Reuben will be honored at the 2025 Research in Action Awards on October 20, 2025, in New York City. The event will also recognize Jeanne Marrazzo, Director of the National Institute of Allergy and Infectious Diseases (NIAID), and longtime TAG board member Richard Lynn. The awards ceremony marks TAG's annual recognition of individuals contributing to HIV, STI, and public health advocacy.MsfaccessPrinciples for Access to Multi-disease Molecular DiagnosticsThe Treatment Action Group (TAG) and Médecins Sans Frontières (MSF) Access Campaign introduced 10 Principles for Access to Multi-disease Molecular Diagnostics to improve access to essential tests for infectious diseases like TB, HIV, and COVID. These principles aim to guide governments, donors, and health actors in creating equitable diagnostic systems, mitigating issues arising from past monopolies in the molecular diagnostics market. Implementing these principles is expected to enhance competition, decrease costs, and ensure fair pricing in the upcoming decade.Baltimore SunJohns Hopkins-led consortium gets $200 million to fight top global health threat: tuberculosisJohns Hopkins Medicine received $200 million in federal funding from USAID to lead the SMART4TB consortium, which will run over five years and fund research on TB diagnostics, treatments, transmission control and prevention. The disease kills an estimated 1.5 million people annually, with case reports down 20% last year while death rates rose. Partners include UCSF, KNCV, the Elizabeth Glaser Pediatric AIDS Foundation and Treatment Action Group.GlobeNewswireTreatment Action Group to Ring The NASDAQ Stock Market Closing BellTreatment Action Group representatives will ring the NASDAQ closing bell on December 8, 2010, at 3:50 p.m. ET. The event coincides with the group's 14th annual Research in Action Awards, honoring AIDS research and activism contributors.